Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Stok Raporu

Piyasa değeri: US$1.3b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Collegium Pharmaceutical Yönetim

Yönetim kriter kontrolleri 4/4

Collegium Pharmaceutical's CEO'su Mike Heffernan, Jan2002 tarihinde atandı, in görev süresi 22.75 yıldır. şirketin hisselerinin 0.087% doğrudan sahiptir ve bu hisselerin değeri $ 1.08M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 10.7 yıldır.

Anahtar bilgiler

Mike Heffernan

İcra Kurulu Başkanı

US$330.6k

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi22.8yrs
CEO sahipliği0.09%
Yönetim ortalama görev süresi5.1yrs
Yönetim Kurulu ortalama görev süresi10.7yrs

Son yönetim güncellemeleri

Recent updates

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

Collegium Pharmaceutical: Thoughts After Another Strategic Move

Feb 20

CEO Tazminat Analizi

Mike Heffernan'un ücretlendirmesi Collegium Pharmaceutical'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$100m

Mar 31 2024n/an/a

US$93m

Dec 31 2023US$331kn/a

US$48m

Sep 30 2023n/an/a

US$9m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$334kn/a

-US$25m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022n/an/a

-US$35m

Mar 31 2022n/an/a

US$43m

Dec 31 2021US$353kn/a

US$72m

Sep 30 2021n/an/a

US$104m

Jun 30 2021n/an/a

US$107m

Mar 31 2021n/an/a

US$42m

Dec 31 2020US$304kn/a

US$27m

Sep 30 2020n/an/a

US$18m

Jun 30 2020n/an/a

US$198k

Mar 31 2020n/an/a

-US$13m

Dec 31 2019US$251kn/a

-US$23m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$22m

Mar 31 2019n/an/a

-US$30m

Dec 31 2018US$5mUS$317k

-US$39m

Sep 30 2018n/an/a

-US$66m

Jun 30 2018n/an/a

-US$62m

Mar 31 2018n/an/a

-US$70m

Dec 31 2017US$3mUS$547k

-US$75m

Tazminat ve Piyasa: Mike 'nin toplam tazminatı ($USD 330.61K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).

Tazminat ve Kazançlar: Mike 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mike Heffernan (60 yo)

22.8yrs

Görev süresi

US$330,614

Tazminat

Mr. Michael Thomas Heffernan, also known as Mike, B.S. Pharm, R.Ph. serve as Independent Director at K36 Therapeutics, Inc. He serves as Lead Independent Director at Biohaven Ltd. since September 2022.Mr....

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Michael Heffernan
Co-Founder22.8yrsUS$330.61k0.087%
$ 1.1m
Colleen Tupper
Executive VP & CFO3.4yrsUS$2.73m0.061%
$ 786.3k
Shirley Kuhlmann
Executive VP6.6yrsUS$2.87m0%
$ 0
Scott Dreyer
Executive VP & Chief Commercial Officer6.3yrsUS$2.61m0%
$ 0
Thomas Smith
Executive VP & Chief Medical Officer2.6yrsUS$2.04m0%
$ 0
Christopher James
Vice President of Investor Relationsno dataVeri yokVeri yok
Bart Dunn
Executive Vice President of Strategy & Corporate Development5.1yrsVeri yokVeri yok
Scott Sudduth
Head of Technical Operations3yrsVeri yokVeri yok

5.1yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: COLL 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Michael Heffernan
Co-Founder21yrsUS$330.61k0.087%
$ 1.1m
John Freund
Independent Director10.7yrsUS$298.61k0.22%
$ 2.8m
Garen Bohlin
Independent Director9.8yrsUS$299.61k0.0073%
$ 93.8k
Gino Santini
Lead Independent Director12.3yrsUS$322.61k0.079%
$ 1.0m
Bill McCarberg
Scientific Advisorno dataVeri yokVeri yok
Nathaniel Katz
Scientific Advisorno dataVeri yokVeri yok
Robert Dworkin
Scientific Advisorno dataVeri yokVeri yok
Lynn Webster
Scientific Advisorno dataVeri yokVeri yok
John Fallon
Independent Director8.3yrsUS$289.61k0.12%
$ 1.5m
Cynthia McCormick
Scientific Advisorno dataVeri yokVeri yok
Richard Rauck
Scientific Advisorno dataVeri yokVeri yok
Charles Argoff
Scientific Advisorno dataVeri yokVeri yok

10.7yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: COLL 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.7 yıldır).